Sign In
Buy VRTX
$428.34
+3.25 (+0.765%)
At Close: Jun 03, 2026
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
10:06am, Wednesday, 04'th Jun 2025
Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
3 No-Brainer Healthcare Stocks to Buy in June
07:00am, Monday, 02'nd Jun 2025
A new month has arrived. Investors now have a fresh opportunity to buy great stocks.
4 Monster Stocks to Buy and Hold for the Next Decade
04:10am, Monday, 02'nd Jun 2025
The U.S. equity market has been anything but calm in 2025, as several factors, including persistent trade tensions, rising macroeconomic uncertainties, and geopolitical challenges, have weighed on ove
2 Top Stocks to Buy Right Now
06:15am, Sunday, 01'st Jun 2025
Some investors are staying away from the market right now due to the volatility stocks have experienced this year and the uncertain near-term economic outlook. Even with these issues, though, stocks a
Vertex Pharmaceuticals Incorporated (VRTX) Bernstein 41st Annual Strategic Decisions Conference (Transcript)
11:01am, Friday, 30'th May 2025
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Bernstein 41st Annual Strategic Decisions Conference May 30, 2025 8:00 AM ET Company Participants Reshma Kewalramani - President & CEO Conference Cal
3 Top Growth Stocks to Buy in the Second Half of 2025
04:46am, Monday, 26'th May 2025
Believe it or not, but we're not far away from being halfway through the year. Time flies when you're having fun -- and when you're not having fun, too.
2 Monster Growth Stocks to Buy and Hold for 10 Years
01:05pm, Saturday, 24'th May 2025
The market's recent correction looks like a massive drop on a year-to-date chart. However, it will look far less daunting in a decade; that's what happens over the long run.
Vertex: Continuing To Dominate In CF, But What About Its Pain Pipeline?
09:46am, Friday, 23'rd May 2025
Vertex Pharmaceuticals Incorporated remains a buy despite recent share price weakness, supported by its dominant cystic fibrosis franchise and robust late-stage pipeline. Alyftrek's launch extends Ver
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030
04:48am, Wednesday, 21'st May 2025
Resilient and growing. Those two descriptions definitely apply to the healthcare sector.
Vertex to Participate in Upcoming Investor Conferences
04:05pm, Thursday, 15'th May 2025
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in three upcoming investor conferences. Susie Lisa, Senior Vice President, Investor
Best Biotech Stocks to Buy in 2025
08:10am, Tuesday, 13'th May 2025
The bear market induced by the Federal Reserve's monetary tightening officially ended in 2023, but it seems no one remembered to tell the biotech sector.
2 Biotech Stocks That Are Screaming Buys in May
07:10am, Tuesday, 13'th May 2025
It's very tempting to pile into the stocks with the strongest positive momentum of the moment -- they've proven themselves and could continue along this path. But in many cases, you could set yourself
This Stock Just Dropped by 12% in 1 Day. History Says This Will Happen Next
04:52am, Tuesday, 13'th May 2025
Vertex Pharmaceuticals (VRTX 3.40%), a leading drugmaker, is performing exceedingly well for the year -- or at least it was, until it released its first-quarter update. The results were not to the mar
Prediction: These 2 Stocks Will Outperform the Market in the Next Five Years
07:08am, Monday, 12'th May 2025
Regardless of how stocks are performing right now, history tells us that the market tends to generate solid returns over long periods. Investors can do even better than the average market performance
My Favorite Tariff Safe-Haven Stock to Buy on the Dip
04:12am, Saturday, 10'th May 2025
Uncertainty has weighed on stocks over the past several weeks, pushing the three major indexes lower -- the S&P 500 (^GSPC -0.07%) even temporarily slid into a bear market. What's driven this negative
